CLINICAL_TRIALS
trial_result
· 2024-04-30
Clinical Trial Update: Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) [Phase 3]
Summary
A Phase 3 study evaluating sparsentan for primary focal segmental glomerulosclerosis has completed and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Travere Therapeutics, Inc. | Conditions: Focal Segmental Glomerulosclerosis | Phase 3 | Status: COMPLETED | Results posted: 2024-04-30